Osteoporosis inducida por corticoides

Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 2010 Apr 14. [Epub ahead of print]. Kok, 2009, Secondary osteoporosis in patients with an osteoporotic fracture, Best Pract Res Clin Rheumatol, 23, 769, 10.1016/j.berh.2009.09.006 Kanis, 2007, The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women, Osteoporos. Int., 18, 1033, 10.1007/s00198-007-0343-y Van Rossum, 2004, Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition, Rec Prog Horm Res, 59, 333, 10.1210/rp.59.1.333 Walsh, 1996, Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study, BMJ, 313, 344, 10.1136/bmj.313.7053.344 Van Staa, 2000, Use of oral corticosteroids in the United Kingdom, Q. J. Med., 93, 105, 10.1093/qjmed/93.2.105 Gudbjornsson, 2002, Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice, Ann. Rheum. Dis., 61, 32, 10.1136/ard.61.1.32 Peat, 1995, Steroid-induced osteoporosis: an opportunity for prevention?, Ann. Rheum. Dis., 54, 66, 10.1136/ard.54.1.66 Buckley, 1999, Prevention of corticosteroid-induced osteoporosis, Arthritis Rheum., 42, 1736, 10.1002/1529-0131(199908)42:8<1736::AID-ANR24>3.0.CO;2-E Curtis, 2005, Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients, Arthritis Rheum., 52, 2485, 10.1002/art.21194 Duyvendak, 2007, Corticosteroid-induced osteoporosis prevention: longitudinal practice patterns in The Netherlands 2001-2005, Osteoporos. Int., 18, 1429, 10.1007/s00198-007-0345-9 Schett, 2010, From bone biology to clinical outcome: stat of the art and future perspectives, Ann. Rheum. Dis., 69, 1415, 10.1136/ard.2010.135061 Roux C. Osteoporosis in inflammatory joint diseases. Osteoporos Int 2010 DOI 10.1007/s00198-010-1319-x. Vosse, 2009, Osteoporosis in rheumatoid arthritis and ankylosing spondylitis, Clin. Exp. Rheumatol., 27, S62 Güler-Yüksel, 2009, Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis, Ann. Rheum. Dis., 68, 330, 10.1136/ard.2007.086348 Arends S, Spoorenberg A, Bruyn GA. The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis. Osteoporos Int 2010 DOI 10.1007/s00198-010-1338-7. Borman, 2008, Bone mineral density and bone turnover in patients with psoriatic arthritis, Clin. Rheumatol., 27, 443, 10.1007/s10067-007-0725-8 Bianchi, 2010, Inflammatory bowel diseases, celiac disease, and bone, Arch. Biochem. Biophys., 503, 54, 10.1016/j.abb.2010.06.026 Ferguson, 2009, Prevalence and progression of osteoporosis in patients with COPD. Results from the Towards a Revolution in COPD Health study, Chest, 136, 1456, 10.1378/chest.08-3016 Dolgos, 2010, Osteoporosis is a prevalent finding in patients with solid organ failure awaiting transplantation: a population-based study, Clin. Transplant., 24, E145, 10.1111/j.1399-0012.2010.01231.x Falkiewicz, 2009, Evolution of bone disease at two years after transplantation: a single-center study, Transplant. Proc., 41, 3063, 10.1016/j.transproceed.2009.09.041 Laan, 1993, Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized controlled study, Ann. Intern. Med., 119, 963, 10.7326/0003-4819-119-10-199311150-00001 LoCascio, 1990, Bone loss in response to long-term glucocorticoid therapy, Bone Miner Res, 8, 39, 10.1016/0169-6009(91)90139-Q Reid, 1992, Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients, Osteoporos. Int., 2, 103, 10.1007/BF01623844 Laan, 1993, Differential effects of glucocorticoids on cortical appendicular and cortical vertebral bone mineral content, Calcif. Tissue Int., 52, 5, 10.1007/BF00675619 Reid, 1990, Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy, Arch. Intern. Med., 150, 2545, 10.1001/archinte.1990.00390230093012 McKenzie, 2000, Decreased bone mineral density during low dose glucocorticoid administration in a randomised-placebo controlled trial, J. Rheumatol., 27, 2222 Van Staa, 2002, The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis, Osteoporos. Int., 13, 777, 10.1007/s001980200108 Buckley, 1996, Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low dose glucocorticoids in patients with rheumatoid arthritis, Ann. Intern. Med., 125, 961, 10.7326/0003-4819-125-12-199612150-00004 Saag, 1998, Alendronate for the prevention and treatment of glucocorticoid induced osteoporosis, N. Engl. J. Med., 339, 292, 10.1056/NEJM199807303390502 Zelissen, 1994, Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison Disease, Ann. Intern. Med., 120, 207, 10.7326/0003-4819-120-3-199402010-00005 Cooper, 1995, Rheumatoid arthritis, corticosteroid therapy and hip fracture, Ann. Rheum. Dis., 54, 49, 10.1136/ard.54.1.49 Hooyman, 1984, Fractures after rheumatoid arthritis, Arthritis Rheum., 27, 1353, 10.1002/art.1780271205 Walsh, 2001, Adverse effects of oral corticosteroids in relation to dose in patients with lung disease, Thorax, 56, 279, 10.1136/thorax.56.4.279 Dykman, 1985, Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases, Arthritis Rheum., 28, 361, 10.1002/art.1780280402 Selby, 2000, Corticosteroids do not alter the threshold for vertebral fracture, J. Bone Miner. Res., 15, 952, 10.1359/jbmr.2000.15.5.952 Verstraeten, 1986, Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effects of low dose corticosteroids, Ann. Rheum. Dis., 45, 852, 10.1136/ard.45.10.852 Adinoff, 1983, Steroid-induced fractures and bone loss in patients with asthma, N. Engl. J. Med., 309, 265, 10.1056/NEJM198308043090502 Luengo, 1991, Vertebral fractures in steroid dependant asthma and involutional osteoporosis: a comparative study, Thorax, 46, 803, 10.1136/thx.46.11.803 Lee, 1994, Osteoporosis and bone morbidity in cardiac transplant recipients, Am. J. Med., 96, 35, 10.1016/0002-9343(94)90113-9 Shane, 1993, Osteoporosis after cardiac transplantation, Am. J. Med., 94, 257, 10.1016/0002-9343(93)90057-V Angeli, 2006, High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study, Bone, 39, 253, 10.1016/j.bone.2006.02.005 Steinbuch, 2004, Oral glucocorticoid use is associated with an increased risk of fracture, Osteoporos. Int., 15, 323, 10.1007/s00198-003-1548-3 Van Staa, 2000, Use of oral corticosteroids and risk of fractures, J. Bone Miner. Res., 15, 993, 10.1359/jbmr.2000.15.6.993 Van Staa, 2000, Fractures and oral corticosteroids: relationship to daily and cumulative dose, Rheumatol., 39, 1383, 10.1093/rheumatology/39.12.1383 Vestergaard, 2003, Corticosteroid use and risk of hip fracture: a population-based case-control study in Denmark, J. Intern. Med., 254, 486, 10.1046/j.1365-2796.2003.01219.x Kanis, 2004, A meta-analysis of prior corticosteroid use and fracture risk, J. Bone Miner. Res., 19, 893, 10.1359/JBMR.040134 Vestergaard, 2005, Fracture risk associated with systemic and topical corticosteroids, J. Intern. Med., 257, 374, 10.1111/j.1365-2796.2005.01467.x De Vries, 2007, Use of inhaled and oral glucocorticoids, severity on inflammatory disease and risk of hip/femur fracture: a population-based case-control study, J. Intern. Med., 261, 170, 10.1111/j.1365-2796.2006.01754.x Gluck, 1981, Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy, Arthritis Rheum., 24, 892, 10.1002/art.1780240705 Haugeberg, 2004, Bone loss in patients treated with pulses of methylprednisolone is not negligible: a short term prospective observational study, Ann. Rheum. Dis., 63, 940, 10.1136/ard.2003.011734 Frediani, 2004, Effects of high dose methylprednisolone pulse therapy on bone mass and biochemical markers of bone metabolism I, patients with active rheumatoid arthritis: a 12-month randomized prospective controlled study, J. Rheumatol., 31, 1083 Zorzon, 2005, Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis, Eur. J. Neurol., 12, 550, 10.1111/j.1468-1331.2005.00988.x Emkey, 1996, The systemic effect of intraarticular administration of corticosteroid on markers of bone formation and bone resorption in patients with rheumatoid arthritis, Arthritis Rheum., 39, 277, 10.1002/art.1780390215 Messina, 1992, Effect of low doses od deflazacort vs prednisone on bone mineral content in premenopausal rheumatoid arthritis, J. Rheumatol., 19, 1520 Olgaard, 1992, Glucocorticoid-induced osteoporosis in lumbar spine, forearm and mandibule of nephrotic patients: a double-blind study on the high-dose, long term effects of prednisone versus deflazacort, Calcif. Tissue Int., 50, 490, 10.1007/BF00582160 van Staa, 2003, Predictors and bone density threshold for vertebral fracture in patients using oral glucocorticoids, Arthritis Rheum., 48, 3224, 10.1002/art.11283 van Staa, 2005, A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids, Q. J. Med., 98, 191, 10.1093/qjmed/hci029 Canalis, 2007, Glucocorticoid-induced osteoporosis: pathophysiology and therapy, Osteoporos. Int., 18, 1319, 10.1007/s00198-007-0394-0 Weinstein, 2010, Glucocorticoids, osteocytes, and skeletal fragility: the role of bone vascularity, Bone, 46, 564, 10.1016/j.bone.2009.06.030 Bressot, 1979, Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis, Metab Bone Dis Rel Res, 1, 303, 10.1016/0221-8747(79)90024-9 Raza K, Hardy R, Cooper MC. The 11β-hydroxysteroid dehydrogenase enzymes - arbiters of the effects of glucocorticoids in synovium and bone. Rheumatology 2010 doi: 10.1093/rheumatology/keq212. Chappard, 1996, Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study, J. Bone Miner. Res., 11, 676, 10.1002/jbmr.5650110516 Chappard, 2007, Bone microarchitecture in males with corticosteroid-induced osteoporosis, Osteoporos. Int., 18, 487, 10.1007/s00198-006-0278-8 Briot, 2009, Vitamine D : effets osseux et extra-osseux; recommandations de bon usage, Presse Med., 38, 43, 10.1016/j.lpm.2008.08.008 Saag, 1998, Alendronate for the prevention and treatment of glucocorticoid induced osteoporosis, N. Engl. J. Med., 339, 292, 10.1056/NEJM199807303390502 Hahn, 1979, Altered mineral metabolism in glucocorticoid-induced osteopenia: effect of 25-hydroxyvitamin D administration, J. Clin. Invest., 64, 655, 10.1172/JCI109506 Meys, 1993, Bone loss after cardiac transplantation: effects of calcium, calcidiol and monofluorophosphate, Osteoporos. Int., 3, 322, 10.1007/BF01637318 Adachi, 1996, Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3-years follow-up, J. Rheumatol., 23, 995 Dykman, 1984, Effect of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in subjects with rheumatic diseases, Arthritis Rheum., 27, 1336, 10.1002/art.1780271203 Sambrook, 1993, Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol and calcitonin, N. Engl. J. Med., 328, 1747, 10.1056/NEJM199306173282404 Amin, 1999, The role of vitamin D in corticosteroid-induced osteoporosis. A meta-analytic approach, Arthritis Rheum., 42, 1740, 10.1002/1529-0131(199908)42:8<1740::AID-ANR25>3.0.CO;2-E de Nijs, 2004, Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D(3) analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies, Osteoporos. Int., 15, 589, 10.1007/s00198-004-1614-5 Roux, 1995, Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss, J. Clin. Endocrinol. Metab., 83, 1128, 10.1210/jcem.83.4.4742 Adachi, 1997, Intermittent etidronate therapy to prevent corticosteroid-induced osteopororsis, N. Engl. J. Med., 337, 382, 10.1056/NEJM199708073370603 Boutsen, 1997, Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial, Calcif. Tissue Int., 61, 266, 10.1007/s002239900334 Ringe, 2003, Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study, Osteoporos. Int., 14, 801, 10.1007/s00198-003-1425-0 Adachi, 2001, Two-years effect of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids, Arthritis Rheum., 44, 202, 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W Cohen, 1999, Risedronate therapy prevents corticosteroid induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo controlled, parallel-group study, Arthritis Rheum., 42, 2309, 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K Reid, 2000, Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid Induced Osteoporosis Treatment Study, J. Bone Miner. Res., 15, 1006, 10.1359/jbmr.2000.15.6.1006 Wallach, 2000, Effect of risedronate on bone mineral density and vertebral fractures in patients receiving glucocorticoids, Calcif. Tissue Int., 67, 277, 10.1007/s002230001146 Reid, 2009, Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial, Lancet, 373, 1253, 10.1016/S0140-6736(09)60250-6 Thomas, 2006, La parathormone en administration intermittente, un traitement anabolique osseux, Rev. Rhum., 73, 444, 10.1016/j.rhum.2005.11.009 Saag, 2007, Teriparatide or alendronate in glucocorticoid-induced osteoporosis, N. Engl. J. Med., 357, 2028, 10.1056/NEJMoa071408 Saag, 2009, Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis, Arthritis Rheum., 11, 3346, 10.1002/art.24879 2001, American College of Rheumatology ad hoc committee on glucocorticoid-induced osteoporosis. Recommandations for the prevention and treatment of glucocorticoid-induced osteoporosis, Arthritis Rheum., 44, 1496, 10.1002/1529-0131(200107)44:7<1496::AID-ART271>3.0.CO;2-5 Adachi, 2000, Management of corticosteroid-induced osteoporosis, Semin. Arthritis Rheum., 29, 228, 10.1016/S0049-0172(00)80011-6 Geusens, 2004, Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology, Ann. Rheum. Dis., 63, 324, 10.1136/ard.2003.008060 Nawata, 2005, Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004), J. Bone Miner. Metab., 23, 105, 10.1007/s00774-004-0596-x Sambrook, 2001, Corticosteroid induced osteoporosis. Guidelines for treatment, Aust. Fam. Physician, 30, 793 Hoes, 2007, EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases, Ann. Rheum. Dis., 66, 1560, 10.1136/ard.2007.072157 Traitement médicamenteux de l'ostéoporose cortisonique. Recommandation de bonne pratique. AFSSAPS. Edition de février 2003 ("http://www.afssaps.fr). Curtis, 2006, Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users, Osteoporos. Int., 17, 1268, 10.1007/s00198-006-0136-8